Core Insights - Chen Tianqiao, founder of the Tianqiao Brain Science Research Institute, has recently invested in a brain-computer interface company called Gestalt, marking a new direction in China's brain-computer interface field using ultrasound technology [1][3] Group 1: Company Overview - Gestalt (Chengdu) Technology Co., Ltd. was officially established on January 1, 2026, co-founded by Peng Lei, former co-founder and CEO of Brain Tiger Technology, and Chen Tianqiao [1] - Gestalt is the first domestic company focused on ultrasound brain-computer interface technology, aiming to explore next-generation full-brain signal reading and writing, and accelerate the commercialization of brain-computer interfaces [1][3] Group 2: Technology and Innovation - The name "Gestalt" is derived from a German philosophical and psychological concept, emphasizing that "the whole is greater than the sum of its parts" [3] - The ultrasound brain-computer interface technology is believed to have the potential for full-brain reading and writing capabilities, allowing for non-invasive precise modulation of specific brain areas [3] - Clinical studies have shown that ultrasound modulation of the anterior cingulate cortex (ACC) significantly reduces pain intensity in chronic pain management, with effects lasting about a week [3] Group 3: Product Development - Gestalt's product plan includes multiple generations, with the first generation being a bench-top device and the second generation being a wearable device, focusing on medical applications [4] - The first product, a magnetic resonance-guided bench-top device, will be used for chronic pain management, with the registration process set to begin this year [4]

"神经连接"公司2024年1月28日完成了该公司首例脑机接口设备人体移植。截至2025 年9月，全球已有12人植入"神经连接"设备，累计使用时间达2000天，总使用时长超过 1.5万小时。 该公司近期表示，临床试验参与者已将控制能力扩展到实体设备，例如辅助型机器人手 臂。随着时间推移，公司计划进一步拓展可通过"神经连接"控制的设备范围。 马斯克：2 0 2 6年将"大规模生产"脑机接口设备。 美国企业家埃隆·马斯克2025年12月31日在社交媒体上表示，其脑机接口公司"神经连 接"将于2026年开始对脑机接口设备进行"大规模生产"，并转向"更加精简和几乎完全自 动化的外科手术流程"。 马斯克说，该设备的电极丝将直接穿过硬脑膜，而无需将其切除，此举意义重大。 End 欢迎分享给你的朋友！ 出品 | 中国能源报（c n e n e rg y） 编辑 | 闫志强 来源：新华社 ...

"神经连接"公司2024年1月28日完成了该公司首例脑机接口设备人体移植。截至2025年9月，全球已有12人植入"神经连接"设备，累计使用时间达2000天， 总使用时长超过1.5万小时。 该公司近期表示，临床试验参与者已将控制能力扩展到实体设备，例如辅助型机器人手臂。随着时间推移，公司计划进一步拓展可通过"神经连接"控制的 设备范围。 当地时间2020年8月28日，马斯克旗下的脑机接口公司"神经连接"（Neuralink）举行发布会，展示了可穿戴设备 LINK V0.9 和手术机器人。视频截图。图 源：视觉中国 据新华社消息，美国企业家埃隆·马斯克2025年12月31日在社交媒体上表示，其脑机接口公司"神经连接"将于2026年开始对脑机接口设备进行"大规模生 产"，并转向"更加精简和几乎完全自动化的外科手术流程"。 马斯克说，该设备的电极丝将直接穿过硬脑膜，而无需将其切除，此举意义重大。 ...

Core Insights - The article discusses the establishment of Gestalt (Chengdu) Technology Co., Ltd., a brain-computer interface (BCI) company founded by Chen Tianqiao and Peng Lei, focusing on ultrasound technology for brain signal reading and writing [1][3]. Group 1: Company Overview - Gestalt is the first domestic company in China to specialize in ultrasound brain-computer interface technology, aiming to accelerate the commercialization of BCI [1]. - The company was officially announced on January 1, 2026, marking a new direction in the field of brain-computer interfaces in China [1]. Group 2: Technology and Innovation - The ultrasound BCI technology is expected to provide a non-invasive method for precise modulation of specific brain regions, which could lead to innovative treatments for brain diseases [3]. - The technology allows for high spatiotemporal resolution recording of brain activity, opening new pathways for fundamental research in neuroscience [4]. Group 3: Clinical Applications - Clinical studies have shown that ultrasound modulation can significantly reduce pain intensity in chronic pain management, with effects lasting approximately one week [4]. - The technology is also being explored for its potential in treating various central nervous system disorders, including depression, Alzheimer's disease, and stroke rehabilitation [4].

该公司披露，截至去年9月，全球已有12位重度瘫痪患者接受植入，能够通过意念控制数字设备与实体 工具。此外，Neuralink还在同年6月获得6.5亿美元融资支持。 据了解，这款植入式设备专为脊髓损伤等患者设计。首位植入者已借助该设备完成玩游戏、浏览网页、 发布社交动态以及操控笔记本电脑光标等一系列操作。 Neuralink于2024年启动人体临床试验，此前公司已解决美国食品药品监督管理局(FDA)提出的安全隐患 ——该机构曾于2022年否决其初始申请。 埃隆马斯克周三在社交平台X发文表示，其旗下脑机接口公司Neuralink将于2026年启动脑机接口设备的 大规模量产，并同步推进手术流程的全自动化改造。 对此，Neuralink暂未就此事回应置评请求。 ...

该公司近期表示，临床试验参与者已将控制能力扩展到实体设备，例如辅助型机器人手臂。随着时间推 移，公司计划进一步拓展可通过"神经连接"控制的设备范围。（完） 马斯克说，该设备的电极丝将直接穿过硬脑膜，而无需将其切除，此举意义重大。 "神经连接"公司2024年1月28日完成了该公司首例脑机接口设备人体移植。截至2025年9月，全球已有12 人植入"神经连接"设备，累计使用时间达2000天，总使用时长超过1.5万小时。 新华社旧金山12月31日电（记者吴晓凌）美国企业家埃隆·马斯克2025年12月31日在社交媒体上表示， 其脑机接口公司"神经连接"将于2026年开始对脑机接口设备进行"大规模生产"，并转向"更加精简和几 乎完全自动化的外科手术流程"。 ...

Core Insights - Neuralink, founded by Elon Musk in 2016, plans to launch large-scale brain-machine interface (BMI) operations by 2026, transitioning to nearly fully automated surgeries [2][3] - The company aims to develop a "full brain interface" that allows seamless connection between the biological brain and external machines, potentially addressing neurological diseases and enhancing human cognitive abilities [4] Company Developments - Neuralink has completed the world's first human BMI implantation trial by the end of 2023 and has outlined detailed plans for the coming years, including advancements in chip technology and electrode counts [2][3] - The company currently has three products: "Mind Reading" for motor impairment patients, "Blind Vision" for visually impaired individuals, and "Deep" for neurological disorders and pain management [3] Future Plans - By Q4 2025, Neuralink aims to implant chips in the speech cortex to decode silent "intent speech" [3] - The number of implanted electrodes is expected to increase from 64 to 3,000 by 2026, and further to 10,000 by 2027, with plans to exceed 25,000 electrodes by 2028 for deeper brain areas [3][4] Domestic Developments - In China, significant advancements in BMI technology have been reported, with 24 financing rounds completed in the BMI sector from January to November 2025, marking a 30% year-on-year increase [5][7] - Various Chinese institutions and companies, such as Shanghai Brain Tiger Technology and Beijing Brain Science Institute, are actively developing and testing BMI technologies [5][6] Investment Trends - The investment enthusiasm in the BMI sector is rising, with over 100 capital firms, including Sequoia and Hillhouse, investing in the field, and a total financing amount exceeding 10 billion yuan in the past five years [7][8] - Neuralink raised $650 million in its E round of financing in June 2025, achieving a post-money valuation of $9 billion, setting a record in the BMI sector [7] Government Support - Government funding is becoming a crucial financing channel for BMI companies, with initiatives like the "BMI Special Incubation Fund" established in Beijing, offering up to 50 million yuan per project [8]

Core Insights - Neuralink, founded by Elon Musk in 2016, plans to launch large-scale brain-machine interface (BMI) operations by 2026, transitioning towards nearly fully automated surgeries [1][2] - The company aims to develop a "full brain interface" that allows seamless connection between the biological brain and external machines, potentially addressing neurological diseases and enhancing human cognitive abilities [4] Group 1: Neuralink's Developments - Neuralink has completed the world's first human BMI implantation trial by the end of 2023 and has outlined detailed plans for the coming years [1] - The company currently has three products: "Mind Reading" for motor impairment patients, "Blind Vision" for visually impaired individuals, and "Deep" for neurological disorders and pain management [3] - Future milestones include implanting speech cortex chips by Q4 2025, increasing electrode counts to 3,000 by 2026, and further expanding to over 25,000 electrodes by 2028 for deeper brain areas [3][4] Group 2: Domestic Progress in BMI Technology - Significant advancements in BMI technology have also been made in China, with multiple companies achieving notable milestones in clinical trials and product development [6][7] - For instance, Shanghai Brain Tiger Technology successfully enabled a patient to play a game using a flexible BMI, and Beijing's Brain Science Institute has implanted their system in multiple spinal injury patients [7] - Despite these advancements, experts caution that invasive BMI clinical trials are still in their early stages, with true brain-machine integration potentially taking 5-10 years to achieve [8] Group 3: Investment Trends in the BMI Sector - Investment enthusiasm in the BMI sector is on the rise, with a reported 30% year-on-year increase in financing activities in 2025, totaling 24 financing events [9][11] - Notable investments include Neuralink's $650 million Series E funding round in June 2025, raising its valuation to $9 billion, and various Chinese companies securing significant funding from venture capital [11][12] - Government funding is also a crucial source of financing for BMI companies, with new special incubation funds being established in multiple cities to support the sector [12]

Core Viewpoint - The article discusses the establishment of Gestalt (Chengdu) Technology Co., Ltd., a company focused on ultrasound brain-computer interface technology, aiming to advance the understanding and treatment of brain-related diseases through innovative non-invasive methods [3][5]. Group 1: Company Overview - Gestalt is the first domestic company specializing in ultrasound brain-computer interface technology in China, with a goal to explore next-generation brain signal reading, writing, and analysis [3][5]. - The company was co-founded by Peng Lei, former co-founder and CEO of Brain Tiger Technology, and Chen Tianqiao, founder of the Tianqiao Brain Science Research Institute [3]. Group 2: Technology and Innovation - The ultrasound brain-computer interface aims to provide non-invasive methods for precise modulation of specific brain regions, which could lead to innovative treatments for various brain diseases [5]. - The technology is based on the concept of "Gestalt," emphasizing that the whole is greater than the sum of its parts, and it seeks to understand the brain as an integrated system rather than isolated regions [5]. Group 3: Clinical Applications - Clinical studies have shown that ultrasound modulation of the anterior cingulate cortex (ACC) can significantly reduce pain intensity in chronic pain management, with effects lasting approximately one week [5]. - The company plans to develop multiple generations of products, starting with a bench-top device for chronic pain management, with registration processes expected to begin this year [6].

Core Insights - The article discusses the establishment of Gestalt (Chengdu) Technology Co., Ltd., a brain-computer interface (BCI) company focused on ultrasound technology, marking a new direction in China's BCI field [1][3] Company Overview - Gestalt is the first domestic company specializing in ultrasound brain-computer interface technology, aiming to explore next-generation full-brain signal reading, writing, and analysis [1][3] - The company was co-founded by Peng Lei, former co-founder and CEO of Brain Tiger Technology, and Chen Tianqiao, founder of Tianqiao Brain Science Research Institute [1][3] Technology and Innovation - The core philosophy of Gestalt is based on the German concept of "Gestalt," emphasizing that the whole is greater than the sum of its parts [1][3] - Ultrasound BCI technology is seen as the most promising direction for achieving full-brain reading and writing capabilities, allowing for non-invasive precision modulation of specific brain areas [3] - The technology aims to provide innovative treatment for various neurological disorders by enabling multi-target modulation of brain circuits [3] Clinical Applications - Clinical interventions using ultrasound BCI have shown effectiveness in managing chronic pain, stroke-related functional impairments, and depression [3] - Research indicates that modulation of the anterior cingulate cortex (ACC) through ultrasound significantly reduces pain intensity, with effects lasting approximately one week [3] Product Development - Gestalt plans to develop its products in multiple generations, starting with a bench-top device followed by a wearable device, focusing on medical applications [4] - The first product, a magnetic resonance-guided bench-top device, will target chronic pain management, with registration processes expected to begin this year [4]